Literature DB >> 11841692

Expression of CTLA-4 by human monocytes.

X-B Wang1, R Giscombe, Z Yan, T Heiden, D Xu, A K Lefvert.   

Abstract

Cytotoxic T lymphocyte-associated molecule-4 (CTLA-4) is a receptor present on T cells that plays a critical role in the downregulation of antigen-activated immune responses. CTLA-4 interacts with the ligands CD80 and CD86 on antigen-presenting cells (APC), and also directs the assembly of inhibitory signalling complexes that lead to quiescence or anergy. In this study, we show that human monocytes constitutively express CTLA-4. About 3% of monocytes expressed CTLA-4 on the cell surface, whereas the intracellular expression was higher and present in about 20% of the monocytes. The sequences of the cDNAs from human monocytes were identical to the sequences of CTLA-4 from T cells. Expression of CTLA-4 was also confirmed in the activated myelomonocytic cell lines U937 and THP-1. Monocytes, but not T cells, activated by interferon (IFN)-gamma also secreted soluble CTLA-4 in vitro. The CTLA-4 expression was upregulated upon treatment with phorbol 12-myristate 13-acetate (PMA) and IFN-gamma. This increased expression could be partially abolished by staurosporine, an inhibitor of protein kinase C (PKC). Ligation of CTLA-4 in the monocyte-like cell-line U937 with antibodies against CTLA-4 partially inhibited the proliferation of cells and the upregulation of cell-surface markers CD86, CD54, HLA-DR and HLA-DQ induced by IFN-gamma and Staphylococcus aureus, Cowan I strain (SAC). Ligation of CTLA-4 suppressed the PMA-stimulated activation of transcription activator protein 1 (AP-1) and nuclear factor (NF)-kappaB in the U937 cell line, indicating the involvement of an inhibitory signal transduction. These data provide the first evidence that CTLA-4 is constitutively expressed by monocytes and thus might be important for the regulation of immune mechanisms associated with monocytes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11841692     DOI: 10.1046/j.0300-9475.2001.01019.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  27 in total

Review 1.  Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.

Authors:  Xiang-Yang Wang; Daming Zuo; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Pharmacother       Date:  2011-12       Impact factor: 3.889

2.  Increased expression of plasma and cell surface co-stimulatory molecules CTLA-4, CD28 and CD86 in adult patients with allergic asthma.

Authors:  C K Wong; S W M Lun; F W S Ko; W K Ip; D S C Hui; C W K Lam
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

Review 3.  Check Point Inhibitors and Their Role in Immunosuppression in Sepsis.

Authors:  Michelle E Wakeley; Chyna C Gray; Sean F Monaghan; Daithi S Heffernan; Alfred Ayala
Journal:  Crit Care Clin       Date:  2019-10-21       Impact factor: 3.598

4.  Lack of intrinsic CTLA-4 expression has minimal effect on regulation of antiviral T-cell immunity.

Authors:  Dirk Homann; Wolfgang Dummer; Tom Wolfe; Evelyn Rodrigo; Argyrios N Theofilopoulos; Michael B A Oldstone; Matthias G von Herrath
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 5.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Authors:  Frank A Schildberg; Sarah R Klein; Gordon J Freeman; Arlene H Sharpe
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

6.  Anti-CTLA4 Antibody Clinical Trials in Melanoma.

Authors:  Antoni Ribas
Journal:  Update Cancer Ther       Date:  2007-09

Review 7.  Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis.

Authors:  A C Foks; J Kuiper
Journal:  Br J Pharmacol       Date:  2017-05-04       Impact factor: 8.739

8.  CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentation.

Authors:  Xiong B Wang; Zhong Z Fan; Doina Anton; Annika V Vollenhoven; Zhen H Ni; Xiao F Chen; Ann K Lefvert
Journal:  BMC Immunol       Date:  2011-03-18       Impact factor: 3.615

9.  Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma.

Authors:  Begoña Comin-Anduix; Hooman Sazegar; Thinle Chodon; Douglas Matsunaga; Jason Jalil; Erika von Euw; Helena Escuin-Ordinas; Robert Balderas; Bartosz Chmielowski; Jesus Gomez-Navarro; Richard C Koya; Antoni Ribas
Journal:  PLoS One       Date:  2010-09-15       Impact factor: 3.240

10.  The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production.

Authors:  Stefania Laurent; Paola Queirolo; Silvia Boero; Sandra Salvi; Patrizia Piccioli; Simona Boccardo; Simona Minghelli; Anna Morabito; Vincenzo Fontana; Gabriella Pietra; Paolo Carrega; Nicoletta Ferrari; Francesca Tosetti; Lung-Ji Chang; Maria Cristina Mingari; Guido Ferlazzo; Alessandro Poggi; Maria Pia Pistillo
Journal:  J Transl Med       Date:  2013-05-01       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.